This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache

This study has been completed.
Ortho-McNeil Neurologics, Inc.
Information provided by:
Janssen-Ortho LLC Identifier:
First received: September 13, 2005
Last updated: May 16, 2011
Last verified: April 2010
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine headache at the earliest onset of headache pain. Almotriptan malate (AXERT®) is approved for the treatment of migraine headache, with or without aura, in adults. Patients in this study will take either almotriptan or placebo oral tablets for 3 consecutive migraine headaches.

Condition Intervention Phase
Migraine Drug: almotriptan malate Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: AXERT® Early miGraine Intervention Study (AEGIS): Efficacy and Safety of Almotriptan Malate (AXERT®) Versus Placebo for the Acute Treatment of Migraine Headache

Resource links provided by NLM:

Further study details as provided by Janssen-Ortho LLC:

Primary Outcome Measures:
  • Effectiveness: pain free at 2 hours (defined as a decrease from severe, moderate or mild to no pain) without the use of supplemental pain medication and/or antiemetic medication up to the 2 hour timepoint

Secondary Outcome Measures:
  • Effectiveness: time to pain free post-dosing; timed assessments to achieve pain relief at 0.5, 1, 2, 4 and 24 hours post-dosing; consistency of response; migraine-associated symptoms; migraine-associated vomiting; change in functional disability

Enrollment: 378
Study Start Date: November 2004
Study Completion Date: June 2005
Detailed Description:

Almotriptan malate (AXERT®) is approved for the treatment of migraine headache, with or without aura, in adults. This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study of adult patients with a diagnosis of migraine headache, with or without aura. Patients will be randomized (like with the toss of a coin) to receive almotriptan malate (AXERT®) or placebo for the treatment of 3 consecutive qualifying migraine headaches. After screening, patients will leave the study center with blinded study medication and an electronic subject diary (Personal Digital Assistant [PDA]). Patients will self-dose with study medication as soon as headache pain of any intensity begins (that resembles their usual migraine), but no later than 1 hour after headache pain begins. Patients will use their PDAs to record assessments such as pain intensity, symptom severity and ability to function as related to the headaches. The primary hypothesis of this study is that the percentage of patients who are pain free two hours after taking study drug at the earliest onset of headache pain is greater in the almotriptan malate (AXERT®) 12.5mg group than in the placebo group and almotriptan malate (AXERT®) is generally well-tolerated.

Almotriptan malate (AXERT®) 12.5 milligrams or placebo tablets, one by mouth at the beginning of migraine pain (within 1 hour) for 3 consecutive migraine headaches


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of migraine, with or without aura
  • At least moderate pain with migraines
  • Average of 2 to 6 migraines per month for past 3 months
  • Duration of headache pain at least 4 hours
  • Able to tell the difference between a migraine and a tension headache
  • If taking a medication to prevent migraines, patients must have been taking a maintenance dose for at least 30 days before screening
  • In generally good health
  • If female, using birth control

Exclusion Criteria:

  • Routinely experience other type of headache that might seem like a migraine headache
  • An average of 15 or more headache days per month in the past 6 months
  • Migraines began after age 50
  • Taking > 1 medicine for preventing migraines
  • Use of any drugs on list of prohibited drugs, of opioid drugs in past 7 days, of corticosteroids in the past 30 days, of an investigational drug within 30 days
  • Use of non-drug treatment for migraine in past 14 days unless have used this treatment for > 14 days and plan to continue throughout study
  • Overuse of medications that treat pain or nausea
  • Migraine aura without headache
  • Hemiplegic or basilar migraines
  • Usually have vomiting with headache
  • Headaches that usually occur upon waking
  • Significant unstable medical disease
  • Abnormal liver, kidney, blood, or ECG laboratory or test results
  • Abusing drugs or alcohol
  • History of a significant mental disorder
  • Pregnant or breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00210509

Sponsors and Collaborators
Janssen-Ortho LLC
Ortho-McNeil Neurologics, Inc.
Study Director: Janssen Ortho LLC Clinical Trial Janssen-Ortho LLC
  More Information

Additional Information:
Publications: Identifier: NCT00210509     History of Changes
Other Study ID Numbers: CR004714
Study First Received: September 13, 2005
Last Updated: May 16, 2011

Keywords provided by Janssen-Ortho LLC:

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on August 23, 2017